ZIM Laboratories has received approval for investment of upto Rs 2 crore in equity shares of ZIMTAS, subsidiary of the company. The Investment is with an objective of Business Development in Australian and New Zealand markets. With the proposed investment, the company’s shareholding in ZIMTAS will change from 99% to 99.97%. The Board of Directors of the company in their meeting held on May 13, 2024 has inter-alia considered and approved the same.
ZIM Laboratories manufactures, formulates, and distributes drug delivery systems to develops generic pharmaceutical products.
